Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis.

ABSTRACT:

Objective

To estimate the cost effectiveness of vaccinating people with high risk conditions against invasive pneumococcal disease using the 13 valent pneumococcal conjugate vaccine.

Design

Economic evaluation using a cohort model from the perspective of healthcare providers.

Setting

England.

Participants

People aged 2 years and older at increased risk of invasive pneumococcal disease due to chronic kidney disease; splenic dysfunction; HIV infection; a compromised immune system; chronic heart, liver, or respiratory disease; or diabetes.

Main outcome measures

Costs, gains in life years and quality adjusted life years (QALYs), and incremental cost effectiveness ratios.

Results

Increasing indirect protection resulting from the vaccination programme o

SUBMITTER: Rozenbaum MH 

PROVIDER: S-EPMC3482156 | biostudies-literature | 2012 Oct

REPOSITORIES: biostudies-literature